Last reviewed · How we verify
Y-6
Y-6 is a small molecule that targets the SGLT2 receptor.
Y-6 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | Y-6 |
|---|---|
| Sponsor | Beijing Tiantan Hospital |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, Y-6 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Trancranial Pulse Stimulation on Anterior Insula Cortex and Dorsal Anterior Cingulate Cortex (NA)
- Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke (PHASE3)
- EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE) (PHASE2)
- Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion (PHASE2)
- Convergent and Concurrent Validity Between Clinical Recovery and Personal-civic Recovery in Mental Health
- Perioperative Electroacupuncture on Postoperative Analgesia in Prostatectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y-6 CI brief — competitive landscape report
- Y-6 updates RSS · CI watch RSS
- Beijing Tiantan Hospital portfolio CI